Slide background
INNOVATING targeting
Slide background
INNOVATING targeting


Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation ... Read all


Philogen will be attending the PEGS Europe Virtual Conference from November 9 to 12, 2020. Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Presentation in the Tumor Microenvironment Session...

Read all


Philogen is a fully integrated company active in the discovery, GMP production and clinical development of targeted therapeutics. We have a leading position in the field of antibody-based therapeutics ... Read all


Philogen has finalized numerous collaborative agreements with large pharmaceutical companies. Read all

Philochem is a fully owned daughter company of Philogen and represents the Discovery Unit of the Philogen group.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy